tiprankstipranks
Trending News
More News >
Innovent Biologics (IVBXF)
OTHER OTC:IVBXF
US Market

Innovent Biologics (IVBXF) Income Statement

Compare
41 Followers

Innovent Biologics Income Statement

Last quarter (Q2 2025), Innovent Biologics's total revenue was ¥5.95B, an increase of 120.36% from the same quarter last year. In Q2, Innovent Biologics's net income was ¥834.32M. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 9.42B¥ 6.21B¥ 4.56B¥ 4.27B¥ 3.84B
Gross Profit
¥ 7.91B¥ 4.40B¥ 3.63B¥ 3.70B¥ 3.46B
Operating Expenses
¥ 7.65B¥ 6.08B¥ 6.21B¥ 5.75B¥ 3.50B
Depreciation and Amortization
¥ 275.60M¥ 385.10M¥ 319.42M¥ 204.75M¥ 85.63M
EBITDA
¥ -480.28M¥ -660.68M¥ -1.75B¥ -2.37B¥ -704.74M
Operating Income
¥ -755.87M¥ -1.68B¥ -3.12B¥ -2.70B¥ -557.18M
Other Income/Expenses
¥ 0.00¥ 534.89M¥ 952.38M¥ 61.63M¥ -301.53M
Pretax Income
¥ -78.62M¥ -1.14B¥ -2.17B¥ -2.64B¥ -858.71M
Net Income
¥ -94.63M¥ -1.03B¥ -2.18B¥ -2.73B¥ -998.42M
Per Share Metrics
Basic EPS
¥ -0.06¥ -0.66¥ -1.46¥ -1.88¥ -0.74
Diluted EPS
¥ -0.06¥ -0.66¥ -1.46¥ -1.88¥ -0.74
Weighted Average Shares Outstanding
1.63B 1.56B 1.49B 1.45B 1.35B
Weighted Average Shares Outstanding (Diluted)
1.63B 1.56B 1.49B 1.46B 1.36B
Currency in CNY

Innovent Biologics Earnings and Revenue History